Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
5 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response.
Gastroenterology. 2010 Sep;139(3):821-7, 827.e1. doi: 10.1053/j.gastro.2010.05.079. Epub 2010 Jun 2.
Gastroenterology. 2010.
PMID: 20621700
Clinical Trial.
Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection.
Mangia A, Minerva N, Bacca D, Cozzolongo R, Agostinacchio E, Sogari F, Scotto G, Vinelli F, Ricci GL, Romano M, Carretta V, Petruzzellis D, Andriulli A.
Mangia A, et al. Among authors: petruzzellis d.
Hepatology. 2009 Feb;49(2):358-63. doi: 10.1002/hep.22679.
Hepatology. 2009.
PMID: 19072829
Item in Clipboard
Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring.
Mangia A, Thompson AJ, Santoro R, Piazzolla V, Copetti M, Minerva N, Petruzzellis D, Mottola L, Bacca D, McHutchison JG.
Mangia A, et al. Among authors: petruzzellis d.
Hepatology. 2011 Sep 2;54(3):772-80. doi: 10.1002/hep.24458. Epub 2011 Jul 21.
Hepatology. 2011.
PMID: 21626525
Clinical Trial.
Item in Clipboard
IL28B CC-genotype association with HLA-DQB1*0301 allele increases the prediction of spontaneous HCV RNA clearance in thalassaemic HCV-infected patients.
Mangia A, Santoro R, Sarli R, Mottola L, Piazzolla V, Petruzzellis D, Bacca D, Clemente R, Copetti M, di Mauro L, Lotti G, Sacco M, Stefano I.
Mangia A, et al. Among authors: petruzzellis d.
Antivir Ther. 2011;16(8):1309-16. doi: 10.3851/IMP1913.
Antivir Ther. 2011.
PMID: 22155912
Item in Clipboard
Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.
Thompson AJ, Santoro R, Piazzolla V, Clark PJ, Naggie S, Tillmann HL, Patel K, Muir AJ, Shianna KV, Mottola L, Petruzzellis D, Romano M, Sogari F, Facciorusso D, Goldstein DB, McHutchison JG, Mangia A.
Thompson AJ, et al. Among authors: petruzzellis d.
Hepatology. 2011 Feb;53(2):389-95. doi: 10.1002/hep.24068. Epub 2011 Jan 10.
Hepatology. 2011.
PMID: 21274861
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite